Ryan Speer 
We are thrilled to share that our own Lance Ballester presented a poster at the Joint Statistical Meetings Annual Conference in Portland, Oregon this past week. His presentation, co-authored by our President, William Martin, was titled “Practical Considerations to Dose Selection in Clinical Trials.” The presentation delved into the critical aspects of dose selection across … Read more
Lotus collaborated with ERG and Concentric in vocacapsaicin bunionectomy trial The Lotus Team is thrilled to have collaborated with both ERG and Concentric on this important trial. We are proud to have played a part in helping advance a potential new treatment for pain management. Congratulations Concentric! Evolution Research Group would like to congratulate our … Read more
We are thrilled to introduce Sandra Winsett as the Director of Clinical Systems at Lotus Clinical Research! Sandra brings over 15 years of experience in the field of clinical systems as well as a deep understanding of the intersection between technology and healthcare. With a degree in Health Informatics and a proven track record of … Read more
Lotus Clinical Research worked closely with Pacira on this successful pivotal Phase 3 trial in bunionectomy, providing scientific consulting and conducting the study within our CRO and the ERG site network.
News & Press Lotus Clinical Research worked closely with Pacira on this successful pivotal Phase 3 trial in total knee arthroplasty (TKA), providing scientific consulting and conducting the study within our CRO and the ERG site network. ERG-Lotus was able enroll this study far more rapidly than a typical TKA study, while employing a relatively … Read more
Below please find my comments on FDA’s draft document: Development of Non-Opioid Analgesics for Acute Pain: Guidance for Industry, dated February 7, 2022. I am a board-certified anesthesiologist and Chief Scientific Officer of Lotus Clinical Research, LLC, a contract research organization, regulatory consulting firm and research site network specializing in analgesic clinical trials.
Lotus Clinical Research worked closely with Innocoll on this successful pivotal Phase 3 trial in abdominoplasty, providing scientific and regulatory consulting and conducting the study within our CRO and the ERG site network.
Lotus Clinical Research worked closely with Innocoll on the design of both new Phase 3 trials, and is currently conducting both studies within our CRO and site network:
Innocoll Biotherapeutics plc Announces First Patients In Phase 3 Clinical Trials for Label Expansion of Xaracoll® (bupivacaine hydrochloride) Implant
Lotus Clinical Research has worked with Concentric for several years and through multiple studies on their novel non-opioid analgesic vocacapsaicin. Recently, Lotus CRO has been instrumental in the study design..
All data used in this analysis is from public sources, and is linked/ cited where possible. INTRODUCTION/ HISTORY Heron Therapeutics’ Zynrelef (formerly called HTX-011) represents the first novel infiltration analgesic approved by FDA since Pacira’s Exparel, which was initially approved in 2011. Heron’s clinical development pathway and regulatory process are therefore of high interest to … Read more
© 2023 Lotus Clinical Research, LLC. All Rights Reserved
